Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SPFPL CECILE THOMAS PHARMACIEN : revenue, balance sheet and financial ratios

SPFPL CECILE THOMAS PHARMACIEN is a French company founded 3 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in CHARBONNIERES-LES-VIEILLES (63410), this company of category PME shows in 2024 a net income positive of 154 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SPFPL CECILE THOMAS PHARMACIEN (SIREN 921508032)
Indicator 2024 2023
Revenue N/C N/C
Net income 153 711 € 387 225 €
EBITDA -3 122 € -3 729 €
Net margin N/C N/C

Revenue and income statement

In 2024, SPFPL CECILE THOMAS PHARMACIEN generates positive net income of 154 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2023-2024: 387 k€ -> 154 k€.

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-3 122 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-3 122 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

153 711 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 29%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 77%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 3.5 years of cash flow to repay all financial debt. This ratio remains within usual banking standards.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

29.173%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

77.311%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

3.518

Solvency indicators evolution
SPFPL CECILE THOMAS PHARMACIEN

Sector positioning

Debt ratio
29.17 2024
2023
2024
Q1: 0.01
Med: 13.69
Q3: 116.56
Average

In 2024, the debt ratio of SPFPL CECILE THOMAS PHARM... (29.17) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
77.31% 2024
2023
2024
Q1: 13.95%
Med: 55.8%
Q3: 90.35%
Good +5 pts over 2 years

In 2024, the financial autonomy of SPFPL CECILE THOMAS PHARM... (77.3%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
3.52 years 2024
2023
2024
Q1: 0.0 years
Med: 0.15 years
Q3: 4.69 years
Average +10 pts over 2 years

In 2024, the repayment capacity of SPFPL CECILE THOMAS PHARM... (3.52) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 9752.14. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

9752.136

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-254.1

Liquidity indicators evolution
SPFPL CECILE THOMAS PHARMACIEN

Sector positioning

Liquidity ratio
9752.14 2024
2023
2024
Q1: 132.35
Med: 897.73
Q3: 5412.13
Excellent

In 2024, the liquidity ratio of SPFPL CECILE THOMAS PHARM... (9752.14) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
-254.1x 2024
2023
2024
Q1: -144.56x
Med: -8.16x
Q3: 0.0x
Average

In 2024, the interest coverage of SPFPL CECILE THOMAS PHARM... (-254.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Positioning of SPFPL CECILE THOMAS PHARMACIEN in its sector

Comparison with sector Fonds de placement et entités financières similaires

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (26 transactions). This range of 431 723€ to 2 978 702€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2024
Indicative
431k€ 1994k€ 2978k€
1 994 821 € Range: 431 723€ - 2 978 702€
NAF 5 année 2024

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 26 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fonds de placement et entités financières similaires)

Compare SPFPL CECILE THOMAS PHARMACIEN with other companies in the same sector:

Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires

Frequently asked questions about SPFPL CECILE THOMAS PHARMACIEN

What is the revenue of SPFPL CECILE THOMAS PHARMACIEN ?

The revenue of SPFPL CECILE THOMAS PHARMACIEN is not publicly disclosed (confidential accounts filed with INPI).

Is SPFPL CECILE THOMAS PHARMACIEN profitable?

Yes, SPFPL CECILE THOMAS PHARMACIEN generated a net profit of 154 k€ in 2024.

Where is the headquarters of SPFPL CECILE THOMAS PHARMACIEN ?

The headquarters of SPFPL CECILE THOMAS PHARMACIEN is located in CHARBONNIERES-LES-VIEILLES (63410), in the department Puy-de-Dome.

Where to find the tax return of SPFPL CECILE THOMAS PHARMACIEN ?

The tax return of SPFPL CECILE THOMAS PHARMACIEN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SPFPL CECILE THOMAS PHARMACIEN operate?

SPFPL CECILE THOMAS PHARMACIEN operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.